New award for acalabrutinib tablets (100 MG) with astrazeneca pharmaceuticals, LP. Period of performance is 06/24/2024 to 06/23/2025 with four one-year options.
Active Indefinite Delivery Contract Awarded Last action
- Contract number
- 36E79724D0026
- Awardee
-
Astrazeneca Pharmaceuticals LP UEI E5K2ZJ8CTJH4
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- 6505--Bruton Tyrosine Kinase (BTK) Inhibitors (VA-24-00023127) Pre-Solicitation · 36E79724R0007 · Posted Jan 24, 2024
- Last date to order 79% complete
- IDV ceiling
- $913,915,470.00
- Award type
- Single award
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 3 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
The Department of Veterans Affairs, through the National Acquisition Center, awarded a single-award indefinite-delivery contract to Astrazeneca Pharmaceuticals LP on June 24, 2024, with a ceiling of $913.9 million for acalabrutinib tablets (100 mg), a Bruton Tyrosine Kinase inhibitor.
The contract has no set-aside designation and runs from June 24, 2024, through June 23, 2025, with four one-year options. The originating solicitation (RFP 36E79724R0007) sought competitive pricing for BTK inhibitors—ibrutinib 140 mg capsules, acalabrutinib 100 mg tablets, or zanubrutinib 80 mg capsules—dosed by units per day for an estimated 2,444 new patients annually. Acalabrutinib was selected as the sole BTK inhibitor listed on relevant agency formularies. The contract serves the Department of Veterans Affairs, Bureau of Prisons, and Indian Health Service. NAICS code 325412 applies (Pharmaceutical Preparation Manufacturing). The second one-year option has been exercised. A modification implementing Executive Order 14398 DEI discrimination clause was issued during performance.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Add Subcontract Plan | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $0 | |
| Add Subcontract Plan | $0 | |
| Other Administrative Action | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36E79724D0026?
36E79724D0026 was awarded to Astrazeneca Pharmaceuticals LP by National Acquisition Center (Headquarters) on June 24, 2024.
How much is contract 36E79724D0026 worth?
36E79724D0026's own ceiling is $913,915,470.
Who can order from contract 36E79724D0026?
36E79724D0026 is a single award indefinite delivery contract.
Was contract 36E79724D0026 competed?
The extent of competition for 36E79724D0026 was full and open competition. The government received 3 offers.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV